NasdaqGS - Nasdaq Real Time Price ? USD
Alkermes plc (ALKS)
As of 3:19 PM EDT. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,507,916.00
1,663,405.00
1,111,795.00
1,173,751.00
1,038,756.00
Cost of Revenue
251,740.00
253,037.00
218,068.00
197,323.00
178,316.00
Gross Profit
1,256,176.00
1,410,368.00
893,727.00
976,428.00
860,440.00
Operating Expense
959,159.00
996,246.00
899,816.00
878,682.00
972,867.00
Operating Income
297,017.00
414,122.00
-6,089.00
97,746.00
-112,427.00
Net Non Operating Interest Income Expense
15,263.00
7,822.00
-5,411.00
-8,811.00
-1,699.00
Other Income Expense
2,374.00
-425.00
-19,628.00
-1,208.00
17,589.00
Pretax Income
314,654.00
421,519.00
-31,128.00
87,727.00
-96,537.00
Tax Provision
-71,058.00
-97,638.00
2,024.00
11,326.00
14,324.00
Net Income Common Stockholders
288,723.00
355,757.00
-158,267.00
-48,169.00
-110,861.00
Diluted NI Available to Com Stockholders
288,723.00
355,757.00
-158,267.00
-48,169.00
-110,861.00
Basic EPS
1.72
2.14
-0.97
-0.30
-0.70
Diluted EPS
1.71
2.10
-0.97
-0.30
-0.70
Basic Average Shares
167,456.00
166,223.00
163,742.00
160,942.00
158,803.00
Diluted Average Shares
170,336.50
169,730.00
163,742.00
160,942.00
158,803.00
Total Operating Income as Reported
297,017.00
414,122.00
-6,089.00
97,746.00
-112,427.00
Total Expenses
1,210,899.00
1,249,283.00
1,117,884.00
1,076,005.00
1,151,183.00
Net Income from Continuing & Discontinued Operation
288,723.00
355,757.00
-158,267.00
-48,169.00
-110,861.00
Normalized Income
385,712.00
519,157.00
-15,969.50
77,643.92
-113,740.85
Interest Income
39,253.00
30,854.00
7,629.00
2,408.00
6,960.00
Interest Expense
23,990.00
23,032.00
13,040.00
11,219.00
8,659.00
Net Interest Income
15,263.00
7,822.00
-5,411.00
-8,811.00
-1,699.00
EBIT
338,644.00
444,551.00
-18,088.00
98,946.00
-87,878.00
EBITDA
390,560.00
519,478.00
59,774.00
177,598.00
-6,024.00
Reconciled Cost of Revenue
218,888.00
213,799.00
176,569.00
156,819.00
135,914.00
Reconciled Depreciation
51,916.00
74,927.00
77,862.00
78,652.00
81,854.00
Net Income from Continuing Operation Net Minority Interest
385,712.00
519,157.00
-33,152.00
76,401.00
-110,861.00
Total Unusual Items Excluding Goodwill
--
--
-21,750.00
-1,427.00
3,945.00
Total Unusual Items
--
--
-21,750.00
-1,427.00
3,945.00
Normalized EBITDA
390,560.00
519,478.00
81,524.00
179,025.00
-9,969.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
--
--
-4,567.50
-184.08
1,065.15
12/31/2020 - 7/16/1991
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
AMPH Amphastar Pharmaceuticals, Inc.
45.72
-2.52%
IRWD Ironwood Pharmaceuticals, Inc.
4.7350
-4.54%
PBH Prestige Consumer Healthcare Inc.
75.29
-0.28%
ITCI Intra-Cellular Therapies, Inc.
72.26
-0.55%
ALIM Alimera Sciences, Inc.
5.55
+0.09%
RDY Dr. Reddy's Laboratories Limited
79.58
-2.63%
COLL Collegium Pharmaceutical, Inc.
37.76
-1.26%
TAK Takeda Pharmaceutical Company Limited
14.93
-0.37%
NBIX Neurocrine Biosciences, Inc.
120.18
-1.93%
PRGO Perrigo Company plc
28.26
-0.81%